Please try another search
Celltrion Healthcare Co., Ltd. operates a biopharmaceutical company in South Korea and internationally. Its biosimilar products include Remsima, Yuflyma, and Remsima SC, which are used for rheumatoid arthritis and inflammatory bowel diseases; Truxima that is used for non-hodgkin’s lymphoma, chronic lymphocytic leukemia, etc.; Herzuma, which is used for metastatic breast and metastatic gastric cancer; and Vegzelma for metastatic colorectal and non-small cell lung cancer. The company also provides novel therapeutics, such as Zymfentra that is used to treat inflammatory bowel disease; and Regkirona for the treatment of COVID-19. In addition, it offers small molecules products for tuberculosis, rare epilepsy, HIV/AIDS, and COVID-19, as well as test kits for COVID-19. The company was formerly known as Nexol, Inc. and changed its name to Celltrion Healthcare Co., Ltd. in March 2009. Celltrion Healthcare Co., Ltd. was founded in 1999 and is headquartered in Incheon, South Korea. Celltrion Healthcare Co., Ltd. is a subsidiary of Celltrion, Inc.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review